Lead Product(s) : Dazucorilant
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Corcept Completes Enrollment in Phase 2 DAZALS Trial for ALS Patients
Details : CORT113176 (dazucorilant) is a selective cortisol modulator under development for amyotrophic lateral sclerosis (ALS), binding to the glucocorticoid receptor but not to other hormone receptors.
Brand Name : CORT113176
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2024
Lead Product(s) : Dazucorilant
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dazucorilant
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
Details : DAZALS is a 198-patient, randomized, double-blind, placebo-controlled Phase 2 trial of dazucorilant in patients with ALS. The primary endpoints will be ALS Functional Rating Scale-Revised (ALSFRS-R) total score and safety.
Brand Name : CORT113176
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 11, 2022
Lead Product(s) : Dazucorilant
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?